Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Doxorubicin 9Specimen Handling 7Sorafenib 7Erlotinib Hydrochloride 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Fluorouracil 5Thalidomide 4Radiofrequency Ablation 4Bevacizumab 4tremelimumab 3cediranib 3cabozantinib 3Trastuzumab 3Pharmacogenomic Testing 3Nivolumab 3Neoadjuvant Therapy 3Melphalan 3MK 2206 3Irinotecan 3Fluorodeoxyglucose F18 3Dasatinib 3Cisplatin 3Chemotherapy, Adjuvant 3Bortezomib 3Biopsy 3AZD 6244 3trametinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Hepatocellular × pevonedistat × Clear all
NCT04175912 2026-05-29

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡